Drug intelligence / Profile preview

kidney stem cell-derived exosomes

Development stage: Preclinical
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Kidney stem cell-derived exosomes (KS-Exo) are an exosome-based therapeutic agent derived from adult kidney stem/progenitor cells. These exosomes have demonstrated therapeutic effects in acute kidney injury (AKI) by activating the hypoxia-inducible factor (HIF) pathway. This activation promotes tubular epithelial cell proliferation and dedifferentiation, suppresses inflammation, and inhibits cisplatin-induced apoptosis in renal tubular cells. Additionally, KS-Exo have been shown to promote general cell proliferation and adhesion, suggesting their potential for kidney regeneration.

Other names: Exosomes derived from kidney stem cells

Targets

HIF3A (Hypoxia-inducible factor 3-alpha)

Beyond the preview

Go deeper on kidney stem cell-derived exosomes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kidney stem cell-derived exosomes.

Explore the full profile